Status: Recruiting
A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
This study is a Phase 1 dose-escalation and dose-confirmation study to evaluate the safety and antitumor activity of UB-VV111. The study will enroll patients with relapsed/refractory large B-cell lymphoma (LBCL) and chronic lymphocytic leukemia (CLL).
Participants needed: 106
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Umoja BiopharmaUpdated: May 28, 2026Locations: 8
Eligibility criteria
18 years or older [+7]
Women who are pregnant or breastfeeding [+8]